There was a time not that long ago when Merck & Co. Inc.’s Keytruda (pembrolizumab), with its multiple cancer indications, was seen as the heir apparent to Humira’s title of the biggest blockbuster drug. Not anymore. That title now belongs to Novo Nordisk A/S’ semaglutide, approved as Ozempic in 2017 to treat diabetes and as Wegovy in 2021 to help with weight loss.
Cutter & CO Brokerage Inc. trimmed its position in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 0.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 291,128 shares of the company’s stock after selling 788 shares during the period. Novo […]
Cutter & CO Brokerage Inc. trimmed its holdings in Novo Nordisk A/S (NYSE:NVO – Free Report) by 0.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 291,128 shares of the company’s stock after selling 788 shares during the period. […]
Schnieders Capital Management LLC raised its holdings in Novo Nordisk A/S (NYSE:NVO – Free Report) by 49.5% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 21,498 shares of the company’s stock after acquiring an additional 7,120 shares during the period. Schnieders Capital Management LLC’s holdings in Novo Nordisk A/S were worth $2,224,000 as […]